Pharmacology/Pharmaceutical Industry
Study shows an increased risk of Guillain-Barré Syndrome with the J&J vaccine; the estimated observed to expected rate ratio was 4.18 for the 42-day window.
8 Oct, 2021 | 10:40h | UTC
Commentary on Twitter
Study suggests a potential small but statistically significant safety concern for #GuillainBarré syndrome following receipt of the @JanssenUS #COVID19 vaccine; findings considered preliminary pending analysis of medical records to establish a definitive Dx https://t.co/yZjJVkp6BA
— JAMA (@JAMA_current) October 7, 2021
Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.
8 Oct, 2021 | 10:29h | UTCRelated:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Commentary on Twitter
As more & more countries consider adding a 3rd #COVID19 vaccine dose into their national immunisation programmes, vaccine reactogenicity will become important, especially if 3rd dose is different to first 2 doses. We need more mix-n-match booster studies 👉https://t.co/G57i9Ej7Nd
— Shamez Ladhani (@ShamezLadhani) October 7, 2021
Ivermectin: How false science created a Covid ‘miracle’ drug.
8 Oct, 2021 | 10:24h | UTCIvermectin: How false science created a Covid ‘miracle’ drug – BBC
Commentary on Twitter
Scientists evaluating ivermectin data for #COVID19
"had not found 'a single clinical trial' claiming to show that ivermectin prevented Covid deaths that did not contain 'either obvious signs of fabrication or errors so critical they invalidate the study'." https://t.co/Xndr6Q5LaS— Isaac Bogoch (@BogochIsaac) October 7, 2021
U.S. Data: Drug-resistant Infections led to $1.9 billion in health care costs, more than 10,000 deaths among older adults in one year.
8 Oct, 2021 | 10:11h | UTCCommentaries:
Study highlights impact of antibiotic resistance on older Americans – CIDRAP
Deprescribing in palliative patients with cancer: a concise review of tools and guidelines.
8 Oct, 2021 | 10:07h | UTC
Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.
7 Oct, 2021 | 10:55h | UTC
Commentary on Twitter
In this 900,000-participant study in Qatar, vaccine effectiveness peaked at 77.5% in the first month after the second dose. The effectiveness fell to as low as 20% in months 5 through 7 after vaccination. #Covid19vaccine #IDTwttier https://t.co/TeDcLLftIH pic.twitter.com/pEBoxs6Hmr
— NEJM (@NEJM) October 6, 2021
Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.
7 Oct, 2021 | 10:51h | UTCCommentary: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD
Related Study: Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine
Commentaries on Twitter
Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons. #Covid19vaccine #IDTwitter https://t.co/EzmsaW2u4Y pic.twitter.com/P95eUm8xo9
— NEJM (@NEJM) October 6, 2021
Just out in @NEJM: Two studies on myocarditis after vaccination with Pfizer
Among 2.5 million vaccinated:
– 54 cases of myocarditis
– 94% men, median 27 y.o.
– Most cases mild, only one fulminanthttps://t.co/xGf7rtwGfr— David Juurlink (@DavidJuurlink) October 6, 2021
Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.
7 Oct, 2021 | 10:49h | UTCMyocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine
Commentary: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD
Related study: Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine
Commentaries on Twitter
In an Israeli Ministry of Health database, 136 cases of myocarditis were detected among 5 million vaccinated persons. #Covid19vaccine #IDTwitter https://t.co/c1wLBCq8UN pic.twitter.com/D2DAGrIuXe
— NEJM (@NEJM) October 6, 2021
Two new @NEJM reports on Pfizer vaccine related myocarditis: very rare (~2 per 100,000) and usually mild; in-depth review of 190 cases, most cases were in males 16-29 years, 2nd dosehttps://t.co/nHgxXTgQ6ohttps://t.co/pchL0VDi4b pic.twitter.com/7pUxNy36Zo
— Eric Topol (@EricTopol) October 6, 2021
Perspective | No one is safe until we are all safe.
7 Oct, 2021 | 10:47h | UTCNo one is safe until we are all safe – Science Translational Medicine
Commentary: Covid ‘still running rampant’ worldwide, warns creator of Oxford vaccine – The Guardian
Related: Opinion: Vaccine Nationalism Harms Everyone and Protects No One
Commentary on Twitter
No one is safe until we all are safe, by Sarah Gilbert @JennerInstitute @NDMOxford @UniofOxford and @DrRHatchett @CEPIVaccines
With a forecast of global vaccine supply for 2021https://t.co/iUgC6euvz6 @ScienceTM a large proportion are Sinopharm and Sinovac from China pic.twitter.com/w4KfUAsU45— Eric Topol (@EricTopol) October 6, 2021
WHO approves first ever malaria vaccine for children at risk.
7 Oct, 2021 | 10:40h | UTCWHO recommends groundbreaking malaria vaccine for children at risk – World Health Organization
Commentaries:
WHO Approves First Ever Malaria Vaccine – Health Policy Watch
In major decision, WHO recommends broad rollout of world’s first malaria vaccine – STAT
Why the WHO approval of the first malaria vaccine is a big deal – Vox
WHO greenlights the world’s first malaria vaccine — but it’s not a perfect shot – NPR
The World Health Organization Just Endorsed The World’s First Malaria Vaccine – TIME
WHO Backs Widespread Use Of First Malaria Vaccine – Forbes
World’s 1st malaria vaccine recommended by WHO – LiveScience
Commentaries on Twitter
I started my career as a #malaria researcher, and I longed for the day that we would have an effective vaccine against this ancient and terrible disease. Today is that day: @WHO is recommending the broad use of the world’s first malaria vaccine. #EndMalaria https://t.co/Oh1O155tYj
— Tedros Adhanom Ghebreyesus (@DrTedros) October 6, 2021
(thread – click for more)
A child dies from #malaria every two minutes.
One death is one too many.🚨 Today, WHO recommends RTS,S, a groundbreaking malaria vaccine, to reduce child illness & deaths in areas with moderate and high malaria transmission https://t.co/xSk58nTIV1#VaccinesWork pic.twitter.com/mSECLtRhQs
— World Health Organization (WHO) (@WHO) October 6, 2021
Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.
7 Oct, 2021 | 10:45h | UTCSweden, Denmark pause Moderna COVID-19 vaccine for younger age groups – Reuters
Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.
7 Oct, 2021 | 10:14h | UTC
EMA recommendations on extra doses and boosters of BioNTech/Pfizer and Moderna mRNA vaccines.
6 Oct, 2021 | 10:15h | UTCComirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency
Related: The difference between COVID-19 ‘third doses’ and ‘boosters’ – Emory News Center
Commentary on Twitter
EMA recommended additional doses and boosters for #Comirnaty and #Spikevax. https://t.co/qefPg2kMMO
In this context, see below what the difference between an additional dose and a #boosterdose is. pic.twitter.com/HeyOACbWXm
— EU Medicines Agency (@EMA_News) October 5, 2021
What we know — and don’t know — about Merck’s new Covid-19 pill.
6 Oct, 2021 | 10:07h | UTCWhat we know — and don’t know — about Merck’s new Covid-19 pill – STAT
Related:
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
Cohort study: Adding a new antihypertensive to existing regimens is associated with greater blood pressure reductions than maximizing dose.
6 Oct, 2021 | 09:57h | UTCNews release: When blood pressure needs more control, what’s better: An additional drug or more of the same? – Michigan Medicine
Commentary on Twitter (thread – click for more)
Excited to see our paper in Annals today looking at blood pressure control regiments by adding multiple low dose meds vs. maxing dose then starting new meds. 🧵 https://t.co/3d4L2nZO4v
— Jeremy Sussman (@JeremySussman) October 5, 2021
SILENCE Randomized Trial: In patients at the end of life, prophylactic subcutaneous scopolamine butylbromide reduces the occurrence of the death rattle (noisy breathing caused by mucus in the upper respiratory tract).
6 Oct, 2021 | 09:54h | UTCEffect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of LifeThe SILENCE Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Preventing Death Rattle With Prophylactic Subcutaneous Scopolamine Butylbromide – JAMA (free for a limited period)
Author interview: Scopolamine Butylbromide for Preventing End-of-Life Death Rattle – JAMA
Commentary on Twitter
In a randomized clinical trial among patients near the end of life, prophylactic subcutaneous scopolamine butylbromide significantly reduced the occurrence of death rattle https://t.co/e6BDI5yirY pic.twitter.com/hHfhC2iYHh
— JAMA (@JAMA_current) October 5, 2021
Systematic review: Pretomanid for tuberculosis.
6 Oct, 2021 | 08:51h | UTCPretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection
Related:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO announces updated definitions of extensively drug-resistant tuberculosis
Supplement: Triumphs of Vaccination.
6 Oct, 2021 | 08:55h | UTCHomepage: Triumphs of Vaccination – The Journal of Infectious Diseases
Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease
The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease
Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible
Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster
Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication
Influenza Vaccines: Successes and Continuing Challenges
Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination
Overview of the United States’ Immunization Program
The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade
The diagnosis and management of endocrine side effects of immune checkpoint inhibitors.
6 Oct, 2021 | 08:44h | UTCRelated: Review: Endocrine complications of immunotherapies
Cohort study: Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older is rare, and most cases are not severe.
5 Oct, 2021 | 10:07h | UTCEditorial: COVID-19 Messenger RNA Vaccination and Myocarditis—A Rare and Mostly Mild Adverse Effect
Commentary on Twitter
New report on very rare acute myocarditis after mRNA vaccination in age 18+
5.8 cases/million after 2nd dose, 0.8/million 1st dose, all cases fully resolved with conservative managementhttps://t.co/Mfh5ImiSpW @KPSCALnews @KPSCalResearch @JAMAInternalMed— Eric Topol (@EricTopol) October 4, 2021
Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.
5 Oct, 2021 | 10:09h | UTCCommentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre
Commentary on Twitter
Study of 3.4 million people @aboutKP @TheLancet
Vaccine efficacy against infections:
– First month post: 88%
– 5 months post: 47%But vaccine efficacy against hospitalization (Figure):
– First month post: 87%
– 5 months post: 88 %https://t.co/1Gse0FKpoI pic.twitter.com/p9wyiaWGeg— Vincent Rajkumar (@VincentRK) October 4, 2021
Video | A Pill For COVID? A Doctor Explains Molnupiravir.
5 Oct, 2021 | 09:57h | UTCA Pill For COVID? | A Doctor Explains Molnupiravir – ZDoggMD
Merck’s Covid-19 pill is great news but may not be a game-changer.
5 Oct, 2021 | 09:59h | UTCMerck’s Covid-19 pill is great news but may not be a game-changer – CNN
AAN Position Statement: Ethical perspectives on costly drugs and health care.
5 Oct, 2021 | 08:57h | UTCEthical Perspectives on Costly Drugs and Health Care: AAN Position Statement – Neurology
News release: AAN Issues Ethics Position Statement on Costly Drugs and Health Care – American Academy of Neurology
Cohort study: Statin therapy initiation linked to increased risk of diabetes progression.
5 Oct, 2021 | 08:56h | UTCCommentaries:
Statin Therapy Initiation and Diabetes Progression – American College of Cardiology
Statin Initiation Linked to Greater Progression of Diabetes – HealthDay
Diabetes progression with initiation of statins – MedicalRessearch.com
Related:
Meta-Analysis: Medications that Reduce or Increase the Risk of New Onset Diabetes
Observational Study Points to an Increased Risk of Diabetes Among Patients Using Statins
Cohort Study: Statin Use Associated with a 38% Higher Risk of Incident Type 2 Diabetes
Commentary on Twitter
Large retrospective matched-cohort study found that #statin use was associated with a higher risk of #diabetes treatment escalation and an increased risk of #hyperglycemic complications https://t.co/lFLz7rVfpd
— JAMA Internal Medicine (@JAMAInternalMed) October 4, 2021